| COV Stock | | | CAD 3.72 0.07 1.85% |
Director
Dr. Ian Brindle is an Independent Director of Covalon Technologies Ltd., with effect from 16 June 2014. Dr. Brindle is the former Vice President of Research, former Dean of Chemistry and has held other academic postings at Brock University since 1968 since 2014.
| Tenure | 10 years |
| Address | 1660 Tech Avenue, Mississauga, ON, Canada, L4W 5S7 |
| Phone | 905 568 8400 |
| Web | https://www.covalon.com |
Brindle is a professor of Chemistry, holds a Chancellor’s Chair in Research Excellence, is a fellow of the Royal Society of Chemistry and is author of more than 70 publications in analytical chemistry. The University of Manchester awarded Dr. Brindle the degree of Doctor of Science for belonging to that group of scientists who “have distinguished themselves as authorities in the field by their substantial and original contributions to the advancement of knowledge.” He also holds a BS from Manchester University and a Masters of Science from Brock University.
Covalon Technologies Management Efficiency
The company has return on total asset
(ROA) of
(0.0325) % which means that it has lost $0.0325 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.0385) %, meaning that it generated substantial loss on money invested by shareholders. Covalon Technologies' management efficiency ratios could be used to measure how well Covalon Technologies manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.18 in 2024.
Return On Capital Employed is likely to drop to -0.22 in 2024. At this time, Covalon Technologies'
Non Current Assets Total are fairly stable compared to the past year.
Other Current Assets is likely to climb to about 637.1
K in 2024, whereas
Non Currrent Assets Other are likely to drop slightly above 115.6
K in 2024.
Covalon Technologies has accumulated 1.56
M in total debt with debt to equity ratio
(D/E) of 2.49, implying the company greatly
relies on financing operations through barrowing. Covalon Technologies has a current ratio of 0.62, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Covalon Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, Covalon Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Covalon Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Covalon to invest in growth at high rates of return. When we think about Covalon Technologies' use of debt, we should always consider it together with cash and equity.
Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, the United Kingdom, Europe, the Middle East, Asia, Latin America, and internationally. It serves hospitals, wound care centers, burn centers, extendedalternate care and acute care facilities, home health care agencies, and physicians offices. COVALON TECHNOLOGIES operates under Biotechnology classification in Exotistan and is traded on Commodity Exchange. Covalon Technologies (COV) is traded on TSX Venture Exchange in Canada and employs 28 people. Covalon Technologies is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Covalon Technologies Leadership Team
Elected by the shareholders, the Covalon Technologies' board of directors comprises two types of representatives: Covalon Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Covalon. The board's role is to monitor Covalon Technologies' management team and ensure that shareholders' interests are well served. Covalon Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Covalon Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Simon Smith, Chief Ltd | |
| John Hands, Senior Director - Global Marketing | |
| Greg Leszczynski, Vice Resources | |
| Brent Ashton, CEO Director | |
| Hamed Abbasian, Vice Development | |
| Ian Brindle, Independent Director | |
| Elaine Zhang, Vice Operations | |
| Mark Doolittle, Senior Operations | |
| Joseph Cordiano, Independent Director | |
| Valerio DiTizio, Co-Founder and Chief Science Officer | |
| Ronald Smith, Director | |
| Gerry Arambula, President Ltd | |
| Emily Hill, Executive CEO | |
| Elinor Caplan, Director | |
| Murray Miller, Independent Director | |
| Kim Crooks, Vice President - Operations | |
| Ron Hebert, VP Marketing | |
| Gale Pollock, Director | |
| Amir CFA, Executive Chairman | |
| Jeffrey Mandel, Independent Director | |
| Myrna Francis, Independent Director | |
| Katie Martinovich, Interim Officer | |
| Danny Brannagan, Chief Financial Officer | |
| Brian Pedlar, President, Chief Executive Officer, Director | |
| John Suk, Director | |
| Ronald Hebert, Senior Marketing | |
| Jason Gorel, Interim Officer | |
| Abe Schwartz, Chairman of The Board, Advisor and Member of Audit Committee | |
Covalon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Covalon Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Covalon Stock Analysis
When running Covalon Technologies' price analysis, check to
measure Covalon Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Covalon Technologies is operating at the current time. Most of Covalon Technologies' value examination focuses on studying past and present price action to
predict the probability of Covalon Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Covalon Technologies' price. Additionally, you may evaluate how the addition of Covalon Technologies to your portfolios can decrease your overall portfolio volatility.